A new PCT patent application claiming new viral protein E7 degraders has been published as WO2022219157A1. The invention was made […]
Category: Uncategorized
Anixa-MolGenie compounds are more potent than the protease inhibitor in Pfizer’s PAXLOVID™ at inhibiting the main protease of SARS-CoV-2
SAN JOSE, Calif. and STUTTGART, Germany, Jan. 24, 2022 /PRNewswire/ — Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused […]
Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant
Dec. 7, 2021 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious […]
Good news for small molecule SARS-CoV-2 virus inhibitors: Pfizer demonstrates clinical efficacy!
Great news for researchers like us that are working on drug candidates to treat SARS-CoV-2 infections. Pfizer could demonstrate that […]
Anixa Biosciences’ Covid-19 Compounds Expected to be Effective Against the Delta Variant
While vaccination has proven to be an effective strategy to prevent Covid-19, the need exists for inexpensive, room-temperature stable, and […]
TUBE Pharmaceuticals and MolGenie collaborate
TUBE Pharmaceuticals GmbH in Vienna, Austria, has developed cytotoxic molecules that are derived from a class of natural products called […]
MolGenie develops new peptide-drug-conjugates (PDC)
MolGenie has currently been assigned the rights to develop and commercialize the rights to a EU-PCT patent application claiming treatments […]
OntoChem Assigns Anixa Covid-19 Drug Discovery Project to MolGenie
HALLE (SAALE), Germany, May 7, 2021 /PRNewswire/ — OntoChem GmbH, a German Life Science IT company, announced today that it has assigned its drug […]